|
| Wednesday, 9 July 2014, 12:00 HKT/SGT | |
| |
|
|
|
HONG KONG, July 9, 2014 - (ACN Newswire) - Target Asset Management Pte., Ltd (TAM), institutional investors of Jintian Pharmaceutical Group, Ltd. (02211.HK), is optimistic about further development of Jintian Pharma and considerably increases its share holdings of Jintian Pharma to 5.09%. TAM is an outstanding fund company established in April 1996, based in Singapore. Teng Ngiek Lian, founder and Chief Investment Officer of TAM, is a former Managing Director of Morgan Grenfell Investment Asia and Managing Director of UBS Assed Management, Singapore. Thus, Mr. Teng possesses more than 40 years of industrial and investment experience in Asia, cultivating his discerning and intelligent eyes in investment. Focusing on the intrinsic value of its investees, TAM invests prudently and precisely through its strict selecting criteria. Demanding and highly disciplined, TAM purchases stocks of institutions that in compliance with its 5 Rs requirement, which are right business, right management, right financial & valuation, right risk/reward ratio and reasonable liquidity. TAM actively searches institutions out of well-organized as well as promising early growth industries at reasonable valuation. According to its "careful yet bold" philosophy of investment, TAM merely concentrates its portfolio on around 30 stocks. It's shown that Value Partner, one of the largest fund management firms in Hong Kong, also owns 7.5% equities of TAM.
Target Asset Management Pte., Ltd, as one of the major shareholders, has hold Jintian Pharma since the IPO and steadily increases the position. According to the shareholding disclosure from HKEX on June 27, TAM invested HKD $5.1 million in order to long 2.08 million shares of Jintian Pharma (with the average price of HKD $2.45 per share).TAM's ownership is now 102 million shares or 5.09% of the issued share capital of the company. It is the first time that the ownership of Jintian has been disclosed, which also indicated that TAM feels optimistic towards the business model and the prospects of Jintian Pharmaceutical Group.
On 12 June, Jintian Pharma was authorized as the general distributor of McJayden in the Greater China Region, and on 22 June, through acquisition, Jintian Pharma became interested in the entire equity interest of Wei Kang which Jintian Pharma has held 64% equity interest in. With a series of cooperation and acquisitions, the company continues to expand its product mix and retail network, leading deeper and broader integration of pharmaceutical value chain in the PRC and attract more institutional investors.
Topic: Press release summary
Sectors: Daily Finance, Daily News, BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
